Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPTI NASDAQ:LXRX NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$8.64-2.4%$7.98$3.65▼$10.99$199.58M0.8379,834 shs294,579 shsLXRXLexicon Pharmaceuticals$2.00+19.0%$1.66$0.51▼$2.00$711.78M0.971.82 million shs6.98 million shsXENEXenon Pharmaceuticals$56.44+0.8%$54.64$28.19▼$63.95$5.41B0.65907,702 shs920,547 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics0.00%+6.50%+22.07%+41.37%+44.84%LXRXLexicon Pharmaceuticals0.00%+4.35%+0.60%+36.59%+148.52%XENEXenon Pharmaceuticals0.00%-0.07%-2.68%+35.33%+58.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$8.64-2.4%$7.98$3.65▼$10.99$199.58M0.8379,834 shs294,579 shsLXRXLexicon Pharmaceuticals$2.00+19.0%$1.66$0.51▼$2.00$711.78M0.971.82 million shs6.98 million shsXENEXenon Pharmaceuticals$56.44+0.8%$54.64$28.19▼$63.95$5.41B0.65907,702 shs920,547 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics0.00%+6.50%+22.07%+41.37%+44.84%LXRXLexicon Pharmaceuticals0.00%+4.35%+0.60%+36.59%+148.52%XENEXenon Pharmaceuticals0.00%-0.07%-2.68%+35.33%+58.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPTIKaryopharm Therapeutics 2.88Moderate Buy$16.1486.84% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.15107.50% UpsideXENEXenon Pharmaceuticals 3.00Buy$74.5032.00% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, LXRX, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026XENEXenon Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $82.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.005/6/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $13.004/27/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.00 ➝ $16.004/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$12.00 ➝ $8.003/25/2026KPTIKaryopharm Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $15.003/25/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $8.003/23/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/16/2026XENEXenon Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$64.00 ➝ $63.003/12/2026LXRXLexicon Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPTIKaryopharm Therapeutics$146.07M1.33N/AN/A($16.00) per share-0.54LXRXLexicon Pharmaceuticals$49.80M17.02N/AN/A$0.30 per share6.67XENEXenon Pharmaceuticals$7.50M727.25N/AN/A$7.53 per share7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPTIKaryopharm Therapeutics-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/11/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.14N/AN/AN/A-37.46%-21.92%-12.70%N/AXENEXenon Pharmaceuticals-$345.91M-$4.36N/AN/AN/AN/A-64.75%-60.02%N/ALatest KPTI, LXRX, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026KPTIKaryopharm Therapeutics-$1.45N/AN/AN/A$31.40 millionN/A5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/A2/13/2026Q4 2025KPTIKaryopharm Therapeutics-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPTIKaryopharm TherapeuticsN/A1.121.08LXRXLexicon Pharmaceuticals0.464.884.87XENEXenon PharmaceuticalsN/A13.4113.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPTIKaryopharm Therapeutics66.44%LXRXLexicon Pharmaceuticals74.70%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipKPTIKaryopharm Therapeutics1.68%LXRXLexicon Pharmaceuticals14.00%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPTIKaryopharm Therapeutics38022.55 million22.17 millionOptionableLXRXLexicon Pharmaceuticals140423.68 million364.37 millionOptionableXENEXenon Pharmaceuticals21096.64 million92.71 millionOptionableKPTI, LXRX, and XENE HeadlinesRecent News About These CompaniesXenon Highlights Positive Phase 3 Azetukalner Seizure Data2 hours ago | theglobeandmail.comXenon Q1 earnings match estimates, pipeline development in focusMay 8 at 7:03 PM | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMay 8 at 3:26 PM | marketbeat.comNeedham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.00May 8 at 8:30 AM | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call TranscriptMay 8 at 4:01 AM | seekingalpha.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 7 at 10:59 PM | finance.yahoo.comXenon (XENE) Q1 2026 Earnings TranscriptMay 7 at 10:59 PM | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings ResultsMay 7 at 10:49 PM | marketbeat.comXenon Reports Q1 2026 Financial Results and Provides Business UpdateMay 7 at 4:01 PM | globenewswire.comXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026May 7 at 8:44 AM | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 3:15 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comJennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comXenon to Report Q1 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)April 30, 2026 | marketbeat.comXenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceApril 26, 2026 | marketbeat.comPeregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENEApril 24, 2026 | marketbeat.comXenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereApril 23, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPTI, LXRX, and XENE Company DescriptionsKaryopharm Therapeutics NASDAQ:KPTI$8.64 -0.21 (-2.37%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$8.39 -0.25 (-2.94%) As of 05/8/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$2.00 +0.32 (+19.05%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.95 -0.05 (-2.40%) As of 05/8/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Xenon Pharmaceuticals NASDAQ:XENE$56.44 +0.44 (+0.79%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$56.38 -0.05 (-0.10%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
